Expert Opinion on Investigational Drugs

Antibody-based therapies as anti-infective agents
pp. 307-321(15)
Author: Casadevall A.

Novel complement inhibitors
pp. 323-332(10)
Authors: Liszewski M.K.; Atkinson J.P.

Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins
pp. 333-348(16)
Authors: Sood R.K.; Fattom A.

Recent advances in immunological adjuvants: the development of particulate antigen delivery systems
pp. 349-359(11)
Author: O'Hagan D.T.

Interleukin-2 in the treatment of malignant melanoma
pp. 361-371(11)
Author: Philip P.A.

Immunoscreening protocols for the identification of clinically useful antibodies and antigens
pp. 373-389(17)
Authors: Mukerjee S.; McKnight M.E.; Glassy M.C.

Urokinase receptor antagonists: novel agents for the treatment of cancer
pp. 391-403(13)
Authors: Weidle U.H.; Knig B.

The therapeutic potential of synthetic multivalent carbohydrates
pp. 405-411(7)
Author: Gardiner J.M.

The role of combinations of HIV protease inhibitors in the management of persons with HIV infection
pp. 413-426(14)
Author: Moyle G.

Ongoing and planned clinical trials of anti-arrhythmic drugs: an update
pp. 427-435(9)
Authors: Schron E.B.; Friedman L.M.; Greene H.L.; Nwachuku C.

Imiquimod 5% cream (Aldara™)
pp. 437-449(13)
Authors: HB S.; ML O.; MA T.; RL M.

A re-evaluation of zalcitabine
pp. 451-462(12)
Author: Moyle G.

Pharmacology of the angiotensin II receptor antagonist, eprosartan
pp. 463-469(7)
Authors: Edwards R.M.; Ruffolo R.R.